Intellia Therapeutics, Inc. Common Stock NTLA
i
Market dataready · fetched 2026-11-07T05:43:19.559Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:26:33.343090764Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T05:43:19.111540+00:00
Intellia Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 13.03 | 92.2% | 16.8% | 10.29 | 91.6% | 12.6% |
| 30Δ | 12.72 | 92.2% | 14.7% | 10.55 | 93.4% | 11.3% |
| 35Δ | 12.42 | 92.4% | 12.8% | 10.81 | 95.1% | 9.9% |
| 40Δ | 12.11 | 92.5% | 10.9% | 11.08 | 96.9% | 8.6% |
| 45Δ | 11.84 | 92.6% | 9.4% | 11.35 | 98.4% | 7.7% |
| 50Δ | 11.59 | 92.7% | 8.2% | 11.63 | 100.0% | 6.7% |
| 55Δ | 11.33 | 92.8% | 7.0% | 11.91 | 101.5% | 5.7% |
| 60Δ | 11.08 | 92.9% | 5.7% | 12.09 | 96.9% | 4.9% |
| 65Δ | 10.80 | 93.8% | 4.8% | 12.23 | 89.2% | 4.2% |
| 70Δ | 10.52 | 95.1% | 4.0% | 12.37 | 81.5% | 3.4% |
| 75Δ | 10.23 | 96.4% | 3.2% | 12.51 | 73.7% | 2.7% |
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 13.03
- IV
- 92.2%
- B/E move
- 16.8%
- Pseudo strike
- 10.29
- IV
- 91.6%
- B/E move
- 12.6%
30Δ
- Pseudo strike
- 12.72
- IV
- 92.2%
- B/E move
- 14.7%
- Pseudo strike
- 10.55
- IV
- 93.4%
- B/E move
- 11.3%
35Δ
- Pseudo strike
- 12.42
- IV
- 92.4%
- B/E move
- 12.8%
- Pseudo strike
- 10.81
- IV
- 95.1%
- B/E move
- 9.9%
40Δ
- Pseudo strike
- 12.11
- IV
- 92.5%
- B/E move
- 10.9%
- Pseudo strike
- 11.08
- IV
- 96.9%
- B/E move
- 8.6%
45Δ
- Pseudo strike
- 11.84
- IV
- 92.6%
- B/E move
- 9.4%
- Pseudo strike
- 11.35
- IV
- 98.4%
- B/E move
- 7.7%
50Δ
- Pseudo strike
- 11.59
- IV
- 92.7%
- B/E move
- 8.2%
- Pseudo strike
- 11.63
- IV
- 100.0%
- B/E move
- 6.7%
55Δ
- Pseudo strike
- 11.33
- IV
- 92.8%
- B/E move
- 7.0%
- Pseudo strike
- 11.91
- IV
- 101.5%
- B/E move
- 5.7%
60Δ
- Pseudo strike
- 11.08
- IV
- 92.9%
- B/E move
- 5.7%
- Pseudo strike
- 12.09
- IV
- 96.9%
- B/E move
- 4.9%
65Δ
- Pseudo strike
- 10.80
- IV
- 93.8%
- B/E move
- 4.8%
- Pseudo strike
- 12.23
- IV
- 89.2%
- B/E move
- 4.2%
70Δ
- Pseudo strike
- 10.52
- IV
- 95.1%
- B/E move
- 4.0%
- Pseudo strike
- 12.37
- IV
- 81.5%
- B/E move
- 3.4%
75Δ
- Pseudo strike
- 10.23
- IV
- 96.4%
- B/E move
- 3.2%
- Pseudo strike
- 12.51
- IV
- 73.7%
- B/E move
- 2.7%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 82.33% | |
| 85.60% | |
| 89.34% | |
| 77.11% | |
| 78.88% | |
| 99.51% | |
| 131.38% | |
| 80.40% | |
| 78.34% | |
| 84.92% | |
| 82.80% | |
| 84.81% | |
| 85.33% | |
| 81.60% | |
| 81.66% | |
| 82.48% | |
| 79.45% | |
| 74.45% | |
| 78.47% | |
| 78.40% | |
| 77.86% | |
| 79.09% | |
| 86.99% | |
| 120.41% | |
| 78.20% | |
| 70.03% | |
| 72.31% | |
| 73.18% | |
| 69.26% | |
| 69.87% | |
| 75.72% | |
| 77.02% | |
| 71.35% | |
| 75.82% | |
| 73.52% | |
| 72.60% | |
| 76.57% | |
| 83.26% | |
| 86.30% | |
| 85.54% | |
| 82.19% | |
| 85.38% | |
| 79.54% | |
| 79.95% | |
| 75.02% | |
| 73.87% | |
| 75.53% | |
| 87.98% | |
| 83.07% | |
| 79.09% | |
| 84.48% | |
| 81.93% | |
| 92.33% |
Biotechnology
NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
More →NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs.…
More →NVCT
Description unavailable
More →OABI
OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. This proprietary technology…
More →OBIO
Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New…
More →OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern,…
More →